Drug · CHEMBL553
Comparisons in its trials132
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 132
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 | 3,780 of 4,661 | 5,279 | NCT05834348 | Trial comparisons |
| Vandetanib vs Erlotinib: Objective Response Rate (ORR) | 75 of 623 | 74 of 617 | 1,240 | NCT00364351 | Trial comparisons |
| Vandetanib vs Erlotinib: Disease Control Rate (DCR) | 254 of 623 | 242 of 617 | 1,240 | NCT00364351 | Trial comparisons |
| Vandetanib vs Erlotinib: serious adverse events | 197 of 623 | 155 of 614 | 1,237 | NCT00364351 | Trial comparisons |
| Tivantinib and Erlotinib vs Placebo and Erlotinib: deaths from any cause | 77 of 520 | 65 of 517 | 1,037 | NCT01244191 | Trial comparisons |
| Tivantinib and Erlotinib vs Placebo and Erlotinib: serious adverse events | 219 of 520 | 191 of 517 | 1,037 | NCT01244191 | Trial comparisons |
| Sunitinib + Erlotinib vs Erlotinib: serious adverse events | 207 of 473 | 181 of 477 | 950 | NCT00457392 | Trial comparisons |
| Erlotinib, 150 mg/Day vs Placebo: serious adverse events | 49 of 433 | 34 of 445 | 878 | NCT00556712 | Trial comparisons |
| Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) vs Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo): serious adverse events | 178 of 436 | 169 of 436 | 872 | NCT01360554 | Trial comparisons |
| Afatinib vs Erlotinib: Number of Participants With Disease Control According to RECIST 1.1 | 201 of 398 | 157 of 397 | 795 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: Number of Participants With Objective Response According to RECIST 1.1 | 22 of 398 | 11 of 397 | 795 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: deaths from any cause | 77 of 392 | 71 of 395 | 787 | NCT01523587 | Trial comparisons |
| Afatinib vs Erlotinib: serious adverse events | 174 of 392 | 175 of 395 | 787 | NCT01523587 | Trial comparisons |
| Bevacizumab + Placebo vs Bevacizumab + Erlotinib: Number of Participants With Any Adverse Events During Post-Chemotherapy Phase | 319 of 367 | 353 of 368 | 735 | NCT00257608 | Trial comparisons |
| Bevacizumab + Placebo vs Bevacizumab + Erlotinib: serious adverse events | 63 of 367 | 86 of 368 | 735 | NCT00257608 | Trial comparisons |
| Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Tumor Response | 24 of 362 | 14 of 358 | 720 | NCT00901901 | Trial comparisons |
| Sorafenib (Nexavar, BAY 43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY 43-9006) + Placebo: Disease Control | 159 of 362 | 188 of 358 | 720 | NCT00901901 | Trial comparisons |
| Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva) vs Sorafenib (Nexavar, BAY43-9006) + Placebo: serious adverse events | 214 of 362 | 198 of 355 | 717 | NCT00901901 | Trial comparisons |
| Erlotinib HCl + Bevacizumab vs Erlotinib HCl + Placebo: deaths from any cause | 258 of 313 | 258 of 313 | 626 | NCT00130728 | Trial comparisons |
| Erlotinib HCl + Bevacizumab vs Erlotinib HCl + Placebo: serious adverse events | 146 of 313 | 121 of 313 | 626 | NCT00130728 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL553/comparisons